Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-10

Clinical Trial Update: A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing adding sitagliptin versus adding dapagliflozin to metformin in type 2 diabetes with mild renal impairment and inadequate glycemic contro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dapagliflozin (dapagliflozin)
  • Sitagliptin (sitagliptin)
  • metformin (metformin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2018-10-10